[Aggressive NK-cell leukemia with CD5(+)CD10(-) monoclonal B cell lymphocytosis and hemophagocytic lymphohistiocytosis: a case report and literature review] [0.03%]
[具有CD5⁺CD10⁻单克隆B细胞淋巴细胞性增多和噬血细胞综合征的侵袭性NK细胞白血病一例并文献复习]
M Liu,X J Liu,Y Zhou et al.
M Liu et al.
Aggressive natural killer (NK) -cell leukemia (ANKL) is a rare hematological malignancy characterized by the abnormal proliferation of NK cells. It progresses rapidly and has a high mortality rate. This article reports the diagnosis and tre...
[Allogeneic hematopoietic stem cell transplantation for RASGRP2 gene-related inherited platelet function disorders: a case report and literature review] [0.03%]
异基因造血干细胞移植治疗RASGRP2基因相关遗传性血小板功能异常性疾病1例及相关文献复习
C L Wang,L H Meng,W Xia et al.
C L Wang et al.
This study retrospectively analyzed a 4-year-and-8-month-old boy with RASGRP2-associated inherited platelet function disorders (IPFD) who was successfully treated with allogeneic hematopoietic stem cell transplantation, along with a review ...
[Epstein-Barr virus-positive nodal T/NK-cell lymphoma presenting with hemophagocytic lymphohistiocytosis: a case report and literature review] [0.03%]
[阳性EB病毒T/自然杀伤细胞淋巴瘤伴噬血细胞综合征1例及文献复习]
J Y Qiu,Y P Liu,H L Mi et al.
J Y Qiu et al.
To enhance our understanding of Epstein-Barr virus (EBV) -positive nodal T/natural killer (NK) cell lymphoma and improve the early recognition and diagnosis of patients presenting with hemophagocytic syndrome (HLH) as the initial manifestat...
[Analysis of the efficacy of half-dose venetoclax combined with reduced-dose HA regimen in the induction therapy of acute myeloid leukemia] [0.03%]
[半剂量venetoclax联合减量HA方案治疗急性髓系白血病诱导缓解疗效分析]
Z S Yan,X H Suo,G C Bai et al.
Z S Yan et al.
We retrospectively analyzed clinical data on newly diagnosed acute myeloid leukemia (AML) patients who received HAV treatment between June 2020 and April 2023. The HAV regimen includes venetoclax at 100 mg on day 0 and 200 mg from day 1 to ...
[Characteristics and survival analysis of 60 cases of primary diffuse large B-cell lymphoma of the breast] [0.03%]
[乳腺原发性弥漫大B细胞淋巴瘤的临床特征及生存分析]
H Q Zhang,J Y He,S Y Chen et al.
H Q Zhang et al.
Objective: To investigate the characteristics and prognostic factors of primary breast diffuse large B-cell lymphoma (PB-DLBCL) . Methods: Clinical data on 60 patients with PB-DLBCL admitted to Ruijin Hospital, affiliated with Shanghai Jiao...
[Long-term outcomes of first-line iFCR regimen in chronic lymphocytic leukemia/small lymphocytic lymphoma and the role of MRD] [0.03%]
一线iFCR方案治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的长期疗效及微小残留灶的作用
M Liu,Y Q Sha,S C Qin et al.
M Liu et al.
Objective: This study aimed to investigate the clinical significance of measurable residual disease (MRD) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with ibrutinib plus fludarabine, cyclophosp...
[Analysis of risk factors for early death in NPM1-mutated acute myeloid leukemia patients] [0.03%]
[NPM1突变急性髓系白血病早期死亡危险因素分析]
L L Wang,M K Shu,X Q Dou et al.
L L Wang et al.
Objective: To investigate the risk factors for early death (ED) in patients with NPM1-mutated acute myeloid leukemia (NPM1(mut) AML) . Methods: A retrospective analysis was conducted on 405 newly diagnosed primary NPM1(mut) AML patients adm...
[Efficacy and safety analysis of avapritinib in children with RUNX1::RUNX1T1 positive-acute myeloid leukemia with KIT mutations] [0.03%]
艾伏替尼治疗携带RUNX1/RUNX1T1融合阳性伴KIT突变的儿童急性髓系白血病疗效和安全性分析
F Y Zheng,M M Ding,A D Lu et al.
F Y Zheng et al.
Objective: To evaluate the efficacy and safety of avapritinib in children with RUNX1::RUNX1T1-positive acute myeloid leukemia (AML) with KIT mutations. Methods: Clinical data on children with RUNX1::RUNX1T1-positive AML with KIT mutations w...
[First-line treatment for chronic graft-versus-host disease: a real-world study] [0.03%]
慢性移植物抗宿主病一线治疗的现实世界研究
X Q Dong,Y D He,S Q Huang et al.
X Q Dong et al.
Objective: To systematically evaluate the efficacy, safety, quality of life, and related influencing factors of first-line treatment in patients with chronic graft-versus-host disease (cGVHD) and to provide evidence-based support for optimi...
[Clinical characteristics and prognostic analysis of adult KMT2A-associated acute myeloid leukemia] [0.03%]
成人KMT2A重排急性髓系白血病的临床特征及预后分析
X Y Zhou,X E Wei,Y Liu et al.
X Y Zhou et al.
Objective: To explore the clinicobiological characteristics and prognostic impact of different fusion partners of KMT2A in acute myeloid leukemia (AML) . Methods: The clinical features of 303 patients with KMT2A-associated AML who received ...